One year after its splashy launch, the AMR Action Fund has made its first investments in a pair of fledgling biotech companies, a key step toward its goal of generating badly needed medicines to combat antibiotic resistance.
The fund is providing an undisclosed portion of its $1 billion in initial backing — much of which comes from several of the world’s largest drug manufacturers — toward Venatorx Pharmaceuticals and Adaptive Phage Therapeutics. The two privately held companies are taking a different approach toward developing therapies that can fight drug-resistant infections.
Create a display name to comment
This name will appear with your comment